Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro
Open Access
- 12 March 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (6) , 1280-1285
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Complement inhibitors in pediatric kidney diseases: new therapeutic opportunitiesPediatric Nephrology, 2023
- Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needsBlood Reviews, 2022
- Eculizumab impairs killing of Neisseria meningitidis serogroup B in atypical hemolytic uremic syndrome patients vaccinated with MenB-4CKidney International, 2022
- Monitoring Ravulizumab effect on complement assaysJournal of Immunological Methods, 2021
- A Novel Case of Complement Factor B DeficiencyJournal of Clinical Immunology, 2020
- Eculizumab and Beyond: The Past, Present, and Future of Complement TherapeuticsTransfusion Medicine Reviews, 2019
- The impact of eculizumab on routine complement assaysJournal of Immunological Methods, 2018
- Expanding horizons in complement drug discovery: challenges and emerging strategiesSeminars in Immunopathology, 2017
- Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumabClinical Immunology, 2017
- Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathyImmunobiology, 2015